Advertisement News Archives - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

News

September 22, 2023

FDA approves Krystal Biotech’s KB408 for AATD treatment

The US Food and Drug Administration (FDA) has granted clearance to Krystal Biotech’s investigational new drug application (IND) for KB408 to treat alpha-1 antitrypsin deficiency (AATD), a rare genetic disease.

FDA approves Krystal Biotech’s KB408 for AATD treatment